Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:KERX

Keryx Biopharmaceuticals (KERX) Stock Price, News & Analysis

Keryx Biopharmaceuticals logo

About Keryx Biopharmaceuticals Stock (NASDAQ:KERX)

Advanced Chart

Key Stats

Today's Range
$2.97
$3.47
50-Day Range
N/A
52-Week Range
$2.47
$5.98
Volume
2.60 million shs
Average Volume
1.69 million shs
Market Capitalization
$344.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive KERX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Keryx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

KERX Stock News Headlines

LBTI Lithium & Boron Technology, Inc.
2024 Biopharmaceutical Industry Landscape
The Coin That Could Define Trump’s Crypto Presidency
When Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”tc pixel
Caliway Biopharmaceuticals Co Ltd 6919
XTL Biopharmaceuticals Ltd ADR XTLB
ImmuneOnco Biopharmaceuticals Shanghai Inc (1541)
Q2 2023 Westrock Coffee Co Earnings Call
See More Headlines

KERX Stock Analysis - Frequently Asked Questions

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) issued its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.15) by $0.01. The biopharmaceutical company earned $28.04 million during the quarter, compared to the consensus estimate of $29.56 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Keryx Biopharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Bristol Myers Squibb (BMY), Amyris (AMRS), Gilead Sciences (GILD), Exelixis (EXEL), Meta Platforms (META) and Immunomedics (IMMU).

Company Calendar

Last Earnings
11/08/2018
Today
8/29/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:KERX
CIK
1114220
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$163.44 million
Net Margins
-96.41%
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-60.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.21
Quick Ratio
1.19

Sales & Book Value

Annual Sales
$60.64 million
Price / Sales
5.67
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.12) per share
Price / Book
-28.00

Miscellaneous

Outstanding Shares
102,380,000
Free Float
N/A
Market Cap
$344.00 million
Optionable
Optionable
Beta
2.35
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:KERX) was last updated on 8/29/2025 by MarketBeat.com Staff
From Our Partners